Diagnosis and treatment of gout in primary care

Practitioner

Volumn 255, Issue 1746, 2011, Pages 17-20

  Rakieh, Chadi ^a   Conaghan, Philip G ^b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

BLOOD; CONFERENCE PAPER; GOUT; HUMAN; PRIMARY HEALTH CARE; RECURRENT DISEASE; RISK FACTOR;

ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GOUT; GOUT SUPPRESSANTS; HUMANS; PRIMARY HEALTH CARE; RECURRENCE; RISK FACTORS; URIC ACID;

EID: 84856266255     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31(8):1582-1587 (Pubitemid 39006641)
2. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41(5):778-799 (Pubitemid 28225778)
3. Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64(2):267-272 (Pubitemid 40197509)
4. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011;23(2):192-202
5. Bhole V, de Vera M, Rahman MM et al. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010;62(4):1069-1076
6. Choi HK, Atkinson K, Karlson EW et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350(11):1093-1103 (Pubitemid 38298989)
7. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum 2007;56(6):2049-2055 (Pubitemid 47110404)
8. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-1324 (Pubitemid 44620440)
9. Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis 2010;69(7):1305-1309
10. Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1301-1311 (Pubitemid 44641591)
11. Roddy E, Mallen CD. Gout. Management in primary care. BMJ 2011;342: d117
12. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46(8):1372-1374
13. Wenham C, Conaghan P. Treating gout: a clinical update. Managing pain in practice 2010;1(2):4-6
14. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64(21):2399-2416 (Pubitemid 39480701)
15. National Institute for Health and Clinical Excellence TA164. Febuxostat for the management of hyperuricaemia in people with gout. NICE. London. 2008
16. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011;377(9760):165-177
17. Becker MA, Schumacher HR, Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353(23):2450-2461 (Pubitemid 41781828)